surmount-1 tirzepatide non-diabetic obesity weight loss 🤔Adults with type 2 diabetes and lose less on EVERY GLP-1 drug compared to those without diabetes, consistently ~5% less. Now that we have retatrutide's TRIUMPH-2 data today we can SURMOUNT-1 Trial - Cardionerds Twitter

Authors Conclusion: weekly treatment with tirzepatide showed significant reduction of the combined end point of cardiovascular mortality and CF worsening compared against placebo, in obese patients with preserved ejection fraction

Kara Andrew, RDN, LDN Medical Reviewer Kara Andrew, RDN, LDN, is the director of health promotion for Memorial Hospital in Carthage, Illinois

A 2019 animal study into the effect of another GLP-1 medication, liraglutide (Victoza, Saxenda), in rats without PMOS showed that the drug decreased certain reproductive hormones and had toxic effects on ovarian tissues

This can lead to a lighter, more optimistic outlook throughout the week

Photo 320293449 Millafedotova | Dreamstime.com

Deficiency in G6PD represents one of the most genetically heterogeneous disorders